My laboratory focuses on studying the immunology and pathogenesis of viral infections and developing novel vaccine and treatment strategies. We have led the development of vaccine candidates for multiple pathogens of global significance, including HIV, Zika virus, tuberculosis, and SARS-CoV-2. We received four NIH U19 Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program grants in 2005, 2008, 2012, and 2018 to construct adenovirus serotype 26 (Ad26) vectors, mosaic immunogens, and Env proteins and to evaluate these vaccine candidates in preclinical and clinical studies. Phase 3 clinical efficacy trials are underway with our mosaic Ad26/Env vaccine. We applied the Ad26 vector to the development of a SARS-CoV-2 vaccine, which led to the J&J Ad26.COV2.S vaccine that is now being utilized throughout the world. We received two NIH U19/UM1 grants in 2011 and 2016 to establish consortia for innovative AIDS research (CIAR) in nonhuman primates and two NIH UM1 Martin Delaney Collaboratory (MDC) grants in 2016 and 2021 to develop HIV-1 cure strategies. In addition, we received Gates Foundation consortium grants consortium grants to develop replicating adenovirus vectors, novel Env protein immunogens, broadly neutralizing antibodies, biomarkers for the viral reservoir, animal models for SARS-CoV-2, pan-coronavirus vaccines, and TB vaccines. My group is a key part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD) and the Ragon Institute of MGH, MIT, and Harvard. I currently serve as Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center and William Bosworth Castle Professor of Medicine and Professor of Immunology, Harvard Medical School.